Suchergebnisse - "Chinn, Leslie W"

PubPharm (29)

1

Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria : a randomized phase 2 trial

enthalten in: Nature medicine | 2021

von Metz, M. | Sussman, G. | Gagnon, R. | +13

2

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus : Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2021

von Isenberg, D. | Furie, R. | Jones, N. | +20

CommentIn: Arthritis Rheumatol. 2021 Oct;73(10):1773-1775. - PMID 34042321

3

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus : Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

enthalten in: Arthritis & Rheumatology | 2021

von Isenberg, D. | Furie, R. | Jones, N. | +20

4

Understanding the Effect of Hydroxypropyl-β-Cyclodextrin on Fenebrutinib Absorption in an Itraconazole-Fenebrutinib Drug-Drug Interaction Study

enthalten in: Clinical pharmacology and therapeutics | 2020

von Durk, M. | Jones, N. | Liu, J. | +8

5

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2020

von Baruch, A. | Wong, C. | Chinn, L. | +12

6

Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib : Understanding Complex Drug-Drug Interactions

enthalten in: CPT: pharmacometrics & systems pharmacology | 2020

von Chen, Y. | Ma, F. | Jones, N. | +6

7

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis : A Randomized, Double-Blind, Phase II Trial (ANDES Study)

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2020

von Cohen, S. | Tuckwell, K. | Katsumoto, T. | +15

8

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

enthalten in: Clinical pharmacology and therapeutics | 2020

von Jones, N. | Yoshida, K. | Salphati, L. | +3

9

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis : A Randomized, Double‐Blind, Phase II Trial

enthalten in: Arthritis & Rheumatology | 2020

von Cohen, S. | Tuckwell, K. | Katsumoto, T. | +15

10

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

enthalten in: Clinical Pharmacology & Therapeutics | 2020

von Jones, N. | Yoshida, K. | Salphati, L. | +3